Phase 4 N=18 Milnacipran for Treatment of Pain in Older Adults With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Pain Rating Index — -3.7 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=208 Long-term Treatment Study of Certolizumab Pegol Without Coadministration of Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients
Rheumatoid Arthritis
Primary: Number of Participants With Adverse Events — 102; 12; 41; 40 participants
N/A N=249 HIV Translating Initiatives for Depression Into Effective Solutions
HIV, Depression
Primary: Percentage of Participants With Depression Treatment Response — 33.3; 17.5 percent response — p=0.003
Phase 2 N=50 Nasal Administration of Sufentanil+Ketamine for Procedure-related Pain in Children
Pain
Primary: Procedural Pain Intensity Score — 3.1 units on a scale
N/A N=23 Retrospective, Non-significant Risk, Deep Brain Stimulation (DBS) Care Management Software Feasibility Study
Parkinson's Disease
Primary: To Characterize the Percentage of Leads in Which the Target Map and the Clinically-derived Activation Map Overlap — 86.5 percentage of leads
Phase 2 N=156 Seroquel for Frequent, Heavy Drinkers
Alcoholism
Primary: TimeLine Follow Back (TLFB) to Measure Percent Heavy Drinking Days During the Medication/Placebo Phase — 20; 24 percent days of heavy drinking — p=.388
N/A N=94 Heart at Home- a Self-care Study
Heart Failure
Primary: Number of HF-related Hospital Days — 0.7; 1.4 number of days
N/A N=53 Efficacy and Safety of Radiofrequency Renal Denervation in Drug Resistant Hypertension
Hypertension
Primary: Change in Office Systolic BP — -31.1 mmHg — p=<0.0001
N/A N=183 Investigating the Safety and Performance of Two New 1-piece Ostomy Products Compared With SenSura 1-piece
Ileostomy - Stoma
Primary: Leakage — 50; 61; 59 percentage of baseplates
Phase 2 N=21 High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1
Chronic Hepatitis C
Primary: Sustained Virological Response, (HCV RNA Neg.) in Serum 24 Weeks Off Therapy. — 3 participants
Phase 2 N=20 Evaluate the Efficacy and Safety of Activated T-lymphocyte Cell Therapy in Advanced Pancreatic Cancer
Pancreatic Cancer
Primary: Disease Control Rate — 25 percentage of participants
Phase 2 N=69 Combined Treatment for Alcohol-Dependent Individuals With PTSD
Stress Disorders, Post-Traumatic · Alcohol Abuse · Substance-Related Disorders
Primary: Heavy Drinking Days/Week — 3.13; 2.89; 1.05; 0.48 Days/Week — p=0.34
Phase 3 N=121 An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)
Sarcoma
Primary: Progression - Free Survival (PFS) — 19.6; 8.3 months
Phase 4 N=39 Efficacy of Pregabalin in Patients With Radicular Pain
Neuropathy; Radicular, Lumbar, Lumbosacral · Failed Back Surgery Syndrome · Spinal Stenosis
Primary: Pain Scores (NRS) at 3-weeks — 6; 3 units on a scale — p=0.279
Early Phase 1 N=80 Human Tissue Distribution of Orally Supplemented Natural Vitamin E Tocotrienol
End Stage Cardiac Failure · Pulmonary Failure · End Stage Liver Disease
Primary: The Levels of TCT in the Tissues of "Non-healthy" Subjects and in the Tissue of "Healthy" Subjects Following Oral Supplementation (200 mg x 2 Per Day for 4-24 Weeks)…